
CJC-1295 + Ipamorelin
A combined research pairing of a long-acting GHRH analog (CJC-1295) with a selective ghrelin-mimetic (Ipamorelin), studied together for their proposed synergistic influence on growth-hormone signaling and recovery pathways.
A combined research pairing of a long-acting GHRH analog (CJC-1295) with a selective ghrelin-mimetic (Ipamorelin), studied together for their proposed synergistic influence on growth-hormone signaling and recovery pathways.
CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog with an extended half-life, while Ipamorelin is a selective ghrelin receptor agonist that stimulates growth-hormone secretion. When studied together, the pairing is explored for its potential to support recovery and repair signaling through coordinated modulation of the somatotropic axis. This is presented as a single combined research entry, not as two separate compounds.
- [1]For educational/research awareness only — not medical or veterinary advice.
Educational Content Only. This information is provided for research awareness and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Always consult a qualified healthcare professional before making any health decisions.
